727 related articles for article (PubMed ID: 19509067)
61. Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma.
Aguirre D; Boya P; Bellet D; Faivre S; Troalen F; Benard J; Saulnier P; Hopkins-Donaldson S; Zangemeister-Wittke U; Kroemer G; Raymond E
Apoptosis; 2004 Nov; 9(6):797-805. PubMed ID: 15505422
[TBL] [Abstract][Full Text] [Related]
62. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
Liu H; Zang C; Schefe JH; Schwarzlose-Schwarck S; Regierer AC; Elstner E; Schulz CO; Scholz C; Possinger K; Eucker J
Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512
[TBL] [Abstract][Full Text] [Related]
63. Synergistic effect of rapamycin and cisplatin in endometrial cancer cells.
Bae-Jump VL; Zhou C; Boggess JF; Gehrig PA
Cancer; 2009 Sep; 115(17):3887-96. PubMed ID: 19484784
[TBL] [Abstract][Full Text] [Related]
64. Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001.
Loehberg CR; Strissel PL; Dittrich R; Strick R; Dittmer J; Dittmer A; Fabry B; Kalender WA; Koch T; Wachter DL; Groh N; Polier A; Brandt I; Lotz L; Hoffmann I; Koppitz F; Oeser S; Mueller A; Fasching PA; Lux MP; Beckmann MW; Schrauder MG
Biochem Pharmacol; 2012 Feb; 83(4):480-8. PubMed ID: 22142888
[TBL] [Abstract][Full Text] [Related]
65. Phospholipase D confers rapamycin resistance in human breast cancer cells.
Chen Y; Zheng Y; Foster DA
Oncogene; 2003 Jun; 22(25):3937-42. PubMed ID: 12813467
[TBL] [Abstract][Full Text] [Related]
66. Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin-resected hepatocellular carcinoma.
Baba HA; Wohlschlaeger J; Cicinnati VR; Hilgard P; Lang H; Sotiropoulos GC; Takeda A; Beckebaum S; Schmitz KJ
Liver Int; 2009 Mar; 29(3):399-405. PubMed ID: 18492014
[TBL] [Abstract][Full Text] [Related]
67. D-glucosamine inhibits proliferation of human cancer cells through inhibition of p70S6K.
Oh HJ; Lee JS; Song DK; Shin DH; Jang BC; Suh SI; Park JW; Suh MH; Baek WK
Biochem Biophys Res Commun; 2007 Sep; 360(4):840-5. PubMed ID: 17624310
[TBL] [Abstract][Full Text] [Related]
68. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
[TBL] [Abstract][Full Text] [Related]
69. Fluvastatin synergistically improves the antiproliferative effect of everolimus on rat smooth muscle cells by altering p27Kip1/cyclin E expression.
Ferri N; Granata A; Pirola C; Torti F; Pfister PJ; Dorent R; Corsini A
Mol Pharmacol; 2008 Jul; 74(1):144-53. PubMed ID: 18413661
[TBL] [Abstract][Full Text] [Related]
70. Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001.
Wedel S; Hudak L; Seibel JM; Juengel E; Tsaur I; Wiesner C; Haferkamp A; Blaheta RA
Life Sci; 2011 Feb; 88(9-10):418-24. PubMed ID: 21192952
[TBL] [Abstract][Full Text] [Related]
71. Rapamycin: an anti-cancer immunosuppressant?
Law BK
Crit Rev Oncol Hematol; 2005 Oct; 56(1):47-60. PubMed ID: 16039868
[TBL] [Abstract][Full Text] [Related]
72. Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells.
Paglin S; Lee NY; Nakar C; Fitzgerald M; Plotkin J; Deuel B; Hackett N; McMahill M; Sphicas E; Lampen N; Yahalom J
Cancer Res; 2005 Dec; 65(23):11061-70. PubMed ID: 16322256
[TBL] [Abstract][Full Text] [Related]
73. Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001.
Baumann P; Hagemeier H; Mandl-Weber S; Franke D; Schmidmaier R
Anticancer Drugs; 2009 Apr; 20(4):259-66. PubMed ID: 19240643
[TBL] [Abstract][Full Text] [Related]
74. Role of the novel mTOR inhibitor RAD001 (everolimus) in anaplastic thyroid cancer.
Papewalis C; Wuttke M; Schinner S; Willenberg HS; Baran AM; Scherbaum WA; Schott M
Horm Metab Res; 2009 Oct; 41(10):752-6. PubMed ID: 19513966
[TBL] [Abstract][Full Text] [Related]
75. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
Verheul HM; Salumbides B; Van Erp K; Hammers H; Qian DZ; Sanni T; Atadja P; Pili R
Clin Cancer Res; 2008 Jun; 14(11):3589-97. PubMed ID: 18519793
[TBL] [Abstract][Full Text] [Related]
76. Mammalian target of rapamycin inhibitors in sarcomas.
Okuno S
Curr Opin Oncol; 2006 Jul; 18(4):360-2. PubMed ID: 16721131
[TBL] [Abstract][Full Text] [Related]
77. Effects of AMPK activation and combined treatment with AMPK activators and somatostatin on hormone secretion and cell growth in cultured GH-secreting pituitary tumor cells.
Tulipano G; Faggi L; Losa M; Mortini P; Spinello M; Sibilia V; Pagani F; Cocchi D; Giustina A
Mol Cell Endocrinol; 2013 Jan; 365(2):197-206. PubMed ID: 23116772
[TBL] [Abstract][Full Text] [Related]
78. The cell toxicity effect of secalonic acid D on GH3 cells and the related mechanisms.
Liao G; Zhou J; Wang H; Mao Z; Xiao W; Wang H; She Z; Zhu Y
Oncol Rep; 2010 Feb; 23(2):387-95. PubMed ID: 20043099
[TBL] [Abstract][Full Text] [Related]
79. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.
Wanner K; Hipp S; Oelsner M; Ringshausen I; Bogner C; Peschel C; Decker T
Br J Haematol; 2006 Sep; 134(5):475-84. PubMed ID: 16856892
[TBL] [Abstract][Full Text] [Related]
80. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.
Del Bufalo D; Ciuffreda L; Trisciuoglio D; Desideri M; Cognetti F; Zupi G; Milella M
Cancer Res; 2006 Jun; 66(11):5549-54. PubMed ID: 16740688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
